Treatment of Crohn's disease with cannabis: an observational study
- PMID: 21910367
Treatment of Crohn's disease with cannabis: an observational study
Erratum in
- Isr Med Assoc J. 2011 Sep;13(9):582. Yablekovitz, Doron [corrected to Yablecovitch, Doron]
Abstract
Background: The marijuana plant cannabis is known to have therapeutic effects, including improvement of inflammatory processes. However, no report of patients using cannabis for Crohn's disease (CD) was ever published.
Objectives: To describe the effects of cannabis use in patients suffering from CD.
Methods: In this retrospective observational study we examined disease activity, use of medication, need for surgery, and hospitalization before and after cannabis use in 30 patients (26 males) with CD. Disease activity was assessed by the Harvey Bradshaw index for Crohn's disease.
Results: Of the 30 patients 21 improved significantly after treatment with cannabis. The average Harvey Bradshaw index improved from 14 +/- 6.7 to 7 +/- 4.7 (P < 0.001). The need for other medication was significantly reduced. Fifteen of the patients had 19 surgeries during an average period of 9 years before cannabis use, but only 2 required surgery during an average period of 3 years of cannabis use.
Conclusions: This is the first report of cannabis use in Crohn's disease in humans. The results indicate that cannabis may have a positive effect on disease activity, as reflected by reduction in disease activity index and in the need for other drugs and surgery. Prospective placebo-controlled studies are warranted to fully evaluate the efficacy and side effects of cannabis in CD.
Similar articles
-
Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease.Am J Gastroenterol. 2009 Nov;104(11):2754-9. doi: 10.1038/ajg.2009.387. Epub 2009 Jul 7. Am J Gastroenterol. 2009. PMID: 19584832
-
Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.Am J Gastroenterol. 1997 Dec;92(12):2203-9. Am J Gastroenterol. 1997. PMID: 9399753 Clinical Trial.
-
Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.Clin Gastroenterol Hepatol. 2003 Mar;1(2):122-8. doi: 10.1053/cgh.2003.50015. Clin Gastroenterol Hepatol. 2003. PMID: 15017504 Clinical Trial.
-
[Treatment of chronic inflammatory bowel diseases].Bull Acad Natl Med. 2007 Jun;191(6):1125-41; discussion 1141. Bull Acad Natl Med. 2007. PMID: 18402168 Review. French.
-
Conventional medical management of inflammatory bowel disease.Gastroenterology. 2011 May;140(6):1827-1837.e2. doi: 10.1053/j.gastro.2011.02.045. Gastroenterology. 2011. PMID: 21530749 Review.
Cited by
-
Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19-A Scoping Review.J Clin Med. 2023 Dec 30;13(1):227. doi: 10.3390/jcm13010227. J Clin Med. 2023. PMID: 38202234 Free PMC article. Review.
-
Therapeutic Potential of Cannabis: A Comprehensive Review of Current and Future Applications.Biomedicines. 2023 Sep 25;11(10):2630. doi: 10.3390/biomedicines11102630. Biomedicines. 2023. PMID: 37893004 Free PMC article. Review.
-
Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review.Crohns Colitis 360. 2023 Sep 26;5(4):otad055. doi: 10.1093/crocol/otad055. eCollection 2023 Oct. Crohns Colitis 360. 2023. PMID: 37867930 Free PMC article.
-
Should gastroenterologists prescribe cannabis? The highs, the lows and the unknowns.World J Clin Cases. 2023 Jun 26;11(18):4210-4230. doi: 10.12998/wjcc.v11.i18.4210. World J Clin Cases. 2023. PMID: 37449231 Free PMC article. Review.
-
A Survey of Cannabis Use among Patients with Inflammatory Bowel Disease (IBD).Int J Environ Res Public Health. 2023 Mar 15;20(6):5129. doi: 10.3390/ijerph20065129. Int J Environ Res Public Health. 2023. PMID: 36982049 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
